Quick Decision: Which FDA Interaction Fits Your Question?
If you are a generic drug developer trying to figure out where to send a question to FDA, the first step is to identify the stage of your product and the type of feedback you need. Use the checklist below to narrow the path before reading the detailed background sections.
- You have a specific development question and have not yet submitted an ANDA — Controlled correspondence is available.
- You received a Complete Response Letter (CRL) and want regulatory or scientific advice — Under GDUFA III, this qualifies as controlled correspondence. This is a change from GDUFA II, where it was general correspondence.
- You received tentative approval and want advice — Under GDUFA III, this qualifies as controlled correspondence.
- Your ANDA is approved and you have a post-approval submission question — Controlled correspondence may apply under GDUFA III.
- You are in an active ANDA review cycle — Controlled correspondence applies only for PSG teleconference follow-ups or Covered Product Authorization (CPA) requests. Everything else is general correspondence.
- You need a broader regulatory strategy discussion — A formal pre-ANDA meeting or other FDA meeting may be more appropriate. Controlled correspondence does not replace these meetings.
Decision Matrix: Controlled Correspondence vs General Correspondence vs Pre-ANDA Meetings
The table below compares the three main interaction types a generic drug developer may consider when deciding how to engage FDA.
| Criterion | Controlled Correspondence | General Correspondence | Pre-ANDA Meeting |
|---|---|---|---|
| What it is | Written request for FDA feedback on a specific element of generic drug development or certain post-approval submission requirements. | All other written inquiries not meeting controlled correspondence criteria, including most inquiries during active ANDA review. | Formal meeting request for broader regulatory and scientific discussion before ANDA submission. |
| When it applies | Pre-ANDA; post-CRL; post-tentative approval; post-approval; during active ANDA review only for PSG teleconference follow-ups or CPA requests. | During active ANDA review for anything other than PSG follow-ups or CPA; other general inquiries. | Before ANDA submission, when a meeting format is preferred over written correspondence. |
| Replaces ANDA submission? | No. It is a feedback channel, not a submission. | No. | No. It does not replace the ANDA. |
| Replaces pre-ANDA meeting? | No. It addresses specific questions, not broad strategy. | No. | N/A — this IS the meeting channel. |
| Response framework | GDUFA III commitment letter performance goals for response timelines. | No GDUFA performance goal framework specific to general correspondence response timing. | GDUFA III pre-ANDA meeting performance goals apply. |
| Key GDUFA III change | Expanded to include post-CRL, post-tentative approval, and post-approval inquiries (previously general correspondence under GDUFA II). | Narrowed: several inquiry types moved to controlled correspondence under GDUFA III. | Separate program under the GDUFA III pre-ANDA enhancements. |
Inference: If your question is narrow and tied to a specific development element or post-approval requirement, controlled correspondence is likely the right channel. If you need a multi-topic strategic discussion, a pre-ANDA meeting is the better fit. Controlled correspondence is not a substitute for either a pre-ANDA meeting or an ANDA submission.
What Is Controlled Correspondence?
Current rule (from FDA source): Controlled correspondence is a correspondence submitted to FDA by or on behalf of a generic drug manufacturer or related industry requesting information on a specific element of generic drug product development or concerning certain post-approval submission requirements. Under the GDUFA III commitment letter, it may be submitted prior to filing an Abbreviated New Drug Application (ANDA).
The FDA GDUFA III Controlled Correspondence Enhancements page is the primary source for this definition and for the program boundaries discussed throughout this article.
Key Expansion: Post-CRL, Post-Tentative Approval, and Post-Approval Inquiries
Attributed event explanation: Under the GDUFA II framework, correspondence seeking regulatory and/or scientific advice after issuance of a Complete Response Letter, after tentative approval, or after ANDA approval was treated as general correspondence. Under GDUFA III, these same types of correspondence can be submitted as controlled correspondence.
This means developers now have a structured, performance-goal-backed pathway for feedback at these later stages, rather than relying solely on general correspondence with no specific response-timeline framework under GDUFA.
Active ANDA Review Boundaries: Eligible vs Ineligible Inquiries
Current rule (from FDA source): During an ANDA assessment cycle, controlled correspondence may be submitted in only two situations:
- The applicant seeks further feedback after a product-specific guidance (PSG) teleconference.
- The applicant seeks a Covered Product Authorization (CPA).
During an active ANDA review, all other correspondence is general correspondence. This is a narrow door — if your question does not fall into one of these two categories while your ANDA is under review, it will not be processed as controlled correspondence.
Preparing the Submission: Guidance and Cover Letter Requirements
Guidance (nonbinding FDA recommendations): FDA has issued two relevant guidance documents. Both are published as Guidance for Industry, which means they represent the agency’s current thinking but are not legally binding requirements.
- Controlled Correspondence Related to Generic Drug Development (March 2024) — provides FDA’s recommendations on the submission and content of controlled correspondence. Read the March 2024 guidance.
- Cover Letter Attachments for Controlled Correspondences and ANDA Submissions (June 2023) — addresses cover letter and attachment expectations for controlled correspondence and ANDA submissions. Also nonbinding FDA guidance.
Both guidances are listed as related resources on the GDUFA III CC Enhancements page. Following these guidances helps ensure your submission is complete and triaged efficiently, but does not guarantee acceptance — FDA performs its own triage review of every submission.
GDUFA III Performance Goals vs Individual Outcome Guarantees
Current rule: The GDUFA III commitment letter provides revised timelines for responding to controlled correspondence, along with definition updates. These timelines are agency performance goals, not guaranteed individual response dates.
It is important to separate two concepts:
- Performance goal — a target the agency commits to meeting at a program level under the GDUFA III commitment letter.
- Guaranteed response date — a specific date by which FDA will respond to your individual submission. GDUFA III does not provide this.
Unknown: The exact response time for any individual controlled correspondence depends on FDA’s workload, the complexity of the question, and triage outcomes. The commitment letter’s performance goals should not be read as a promise of a specific date for your submission.
What Controlled Correspondence Does Not Replace
Inference: Controlled correspondence is a targeted feedback channel. Its scope is explicitly limited to specific elements of drug development or certain post-approval requirements. It does not replace:
- A pre-ANDA meeting — for broader regulatory strategy discussions, a formal meeting is the appropriate channel.
- An ANDA submission — controlled correspondence is a question-and-answer mechanism, not an application.
Treating controlled correspondence as a substitute for either would misrepresent its purpose and could leave development questions unaddressed through the proper channel.
Blocked Claims and Compliance Guardrails
To keep this article accurate and within its evidence-backed scope, the following claims are explicitly blocked and not made anywhere in this article:
- This article does not provide legal advice or guarantee any FDA outcome decision.
- This article does not present GDUFA III performance goals as absolute statutory deadlines for individual submissions.
- This article does not suggest that controlled correspondence replaces formal pre-ANDA meetings or ANDA applications.
- This article does not guarantee that a submission will be accepted without formal FDA triage review.
Future event: GDUFA IV (fiscal years 2028-2032) may introduce further changes to the controlled correspondence program. The FDA page already lists GDUFA IV reauthorization as a related topic. Until GDUFA IV terms are finalized and published, the GDUFA III framework described here remains in effect.
Sources
- U.S. Food and Drug Administration. GDUFA III Controlled Correspondence Enhancements. Content current as of 2026-07-22. Accessed 2026-07-31.
- U.S. Food and Drug Administration. Controlled Correspondence Related to Generic Drug Development — Guidance for Industry, March 2024. Accessed 2026-07-31.
- U.S. Food and Drug Administration. GDUFA III CC Enhancements — Related Resources (June 2023 Cover Letter Attachments guidance, March 2024 CC guidance, and explanatory presentation). Accessed 2026-07-31.
- U.S. Food and Drug Administration. GDUFA III CC Enhancements — Active ANDA Review Boundaries (PSG and CPA). Accessed 2026-07-31.